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Various critical events, liver related or not, occur in patients with compensated
cirrhosis, but their respective burden remains to be prospectively assessed. The aim
of this prospective cohort study involving 35 French centers was to capture the whole
spectrum of complications occurring in compensated viral cirrhosis (VC) using
competing risks analyses. Inclusion criteria were: histologically proven cirrhosis
resulting from hepatitis C virus (HCV) or hepatitis B virus (HBV); Child-Pugh A; and
no previous hepatic complications. The cohort was considered as a multistate disease
model, cumulative incidences (CumIs) of events were estimated in a competing risks
framework. A total of 1,654 patients were enrolled from 2006 to 2012 (HCV, 1,308;
HBV, 315; HCV-HBV, 31). During a median follow-up of 34 months, at least one liver
nodule was detected in 271 patients, confirmed as hepatocellular carcinoma (HCC) in
128 (4-year cumI: 10.5%) and cholangiocarcinoma in 3. HCC incidence was higher in
HCV (4-year cumI: 11.4% vs. 7.4%; P = 0.05). HCC fulfilled Milan criteria in 79.3%,
leading to curative treatment in 70.4%. Liver decompensation occurred more
frequently in HCV patients (4-year cumI: 10.8% vs. 3.6%; P = 0.0004). Virological
eradication/control was achieved in 34.1% of HCV and 88.6% of HBV patients and
was associated with a marked decrease in HCC, decompensation, and bacterial
infection incidences. Survival was shorter in HCV patients (4-year cumI: 91.6% vs.
97.2%; P = 0.0002). Death (n = 102; missing data: 6) was attributed to liver disease in
48 (47%; liver cancer: n = 18; miscellaneous, n = 30) and extrahepatic causes in 48
(47%; bacterial infection: n = 13; extrahepatic cancers: n = 10; cardiovascular events:
n = 5; miscellaneous, n = 20).
CONCLUSION: After 3 years of follow-up, extrahepatic events still explained half of
deaths in patients with compensated VC. A strong decrease in complications was
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